R&D Update

Significant new opportunities for growth Paris, France and Camberley, UK – 27 July 2020 – Novacyt (EURONEXT GROWTH:ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an R&Dupdate. http://novacyt.com/wp-content/uploads/2020/07/Novacyt-RD-Update-27-07-20-ENGLISH.pdf

Visit Page

2,000 patient clinical trial using Novacyt’s nearpatient testing system initiated in London care homes

Paris, France and Camberley, UK – 22 July 2020 – Novacyt (EURONEXT GROWTH:ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, notes the initiationof a clinical trial by Queen Mary University of London using the Company’s innovative nearpatienttesting system. The study is investigating whether daily COVID-19 testing reducesthe infection rate, morbidity and mortality in the

Visit Page

Half-Year Trading Update

Sales growth of more than 900%, debt-free andsignificantly cashflow positiveDemand for COVID-19 test expected to continue into 2021 Paris, France and Camberley, UK – 13 July 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an unaudited trading update for the six months ended 30 June 2020. http://novacyt.com/wp-content/uploads/2020/07/Novacyt-H1-2020-Trading-Update-13-07-2020-ENGLISH.pdf

Visit Page